
Sergio Coffa
Examiner (ID: 9639, Phone: (571)270-3022 , Office: P/1675 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1676, 1658, 1654, 1675 |
| Total Applications | 874 |
| Issued Applications | 431 |
| Pending Applications | 148 |
| Abandoned Applications | 341 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17792051
[patent_doc_number] => 20220251142
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/549579
[patent_app_country] => US
[patent_app_date] => 2021-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32394
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17549579
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/549579 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Dec 12, 2021 | Pending |
Array
(
[id] => 17670946
[patent_doc_number] => 20220184113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/546177
[patent_app_country] => US
[patent_app_date] => 2021-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12470
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17546177
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/546177 | RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF | Dec 8, 2021 | Abandoned |
Array
(
[id] => 17640659
[patent_doc_number] => 20220168397
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF
[patent_app_type] => utility
[patent_app_number] => 17/545870
[patent_app_country] => US
[patent_app_date] => 2021-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41655
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545870
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/545870 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | Dec 7, 2021 | Pending |
Array
(
[id] => 19339305
[patent_doc_number] => 12049483
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-30
[patent_title] => Selective and noncovalent inhibitors of oncogenic RAS mutants
[patent_app_type] => utility
[patent_app_number] => 17/543464
[patent_app_country] => US
[patent_app_date] => 2021-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 14
[patent_no_of_words] => 14830
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17543464
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/543464 | Selective and noncovalent inhibitors of oncogenic RAS mutants | Dec 5, 2021 | Issued |
Array
(
[id] => 17482173
[patent_doc_number] => 20220089677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => ANTI-KRAS-G12D T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 17/541619
[patent_app_country] => US
[patent_app_date] => 2021-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18685
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541619
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/541619 | Anti-KRAS-G12D T cell receptors | Dec 2, 2021 | Issued |
Array
(
[id] => 18922944
[patent_doc_number] => 20240025948
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => ADHESIVE PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/038936
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038936
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/038936 | ADHESIVE PEPTIDES | Nov 21, 2021 | Pending |
Array
(
[id] => 18922944
[patent_doc_number] => 20240025948
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => ADHESIVE PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/038936
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038936
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/038936 | ADHESIVE PEPTIDES | Nov 21, 2021 | Pending |
Array
(
[id] => 17687709
[patent_doc_number] => 20220195001
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => NOVEL ANTIMICROBIAL AND ANTI-CANCER THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/531100
[patent_app_country] => US
[patent_app_date] => 2021-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12945
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531100
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/531100 | Antimicrobial and anti-cancer therapy | Nov 18, 2021 | Issued |
Array
(
[id] => 17625924
[patent_doc_number] => 20220160939
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => SELF-ASSEMBLING PEPTIDES AS BRONCHIAL OBSTRUCTION AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/529600
[patent_app_country] => US
[patent_app_date] => 2021-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18875
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529600
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/529600 | SELF-ASSEMBLING PEPTIDES AS BRONCHIAL OBSTRUCTION AGENTS | Nov 17, 2021 | Abandoned |
Array
(
[id] => 17580207
[patent_doc_number] => 20220137062
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => KIT FOR PREPARING SAMPLE FOR DETECTING MONOCLONAL ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/455089
[patent_app_country] => US
[patent_app_date] => 2021-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14707
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 164
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17455089
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/455089 | Kit for preparing sample for detecting monoclonal antibody | Nov 15, 2021 | Issued |
Array
(
[id] => 17548151
[patent_doc_number] => 20220119492
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => IL-2R-BETA-GAMMA BINDING COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/519278
[patent_app_country] => US
[patent_app_date] => 2021-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88960
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519278
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/519278 | IL-2R-BETA-GAMMA BINDING COMPOUNDS AND USES THEREOF | Nov 3, 2021 | Abandoned |
Array
(
[id] => 17428367
[patent_doc_number] => 20220056075
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => METHOD FOR TREATING OPIOID USE DISORDER
[patent_app_type] => utility
[patent_app_number] => 17/518047
[patent_app_country] => US
[patent_app_date] => 2021-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15387
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17518047
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/518047 | METHOD FOR TREATING OPIOID USE DISORDER | Nov 2, 2021 | Pending |
Array
(
[id] => 17548110
[patent_doc_number] => 20220119451
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => Polypeptides And Compositions Comprising The Same
[patent_app_type] => utility
[patent_app_number] => 17/507301
[patent_app_country] => US
[patent_app_date] => 2021-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9559
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17507301
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/507301 | Polypeptides and compositions comprising the same | Oct 20, 2021 | Issued |
Array
(
[id] => 18808615
[patent_doc_number] => 20230382949
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => LINEAR APELIN RECEPTOR AGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/031416
[patent_app_country] => US
[patent_app_date] => 2021-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 324
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031416
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/031416 | LINEAR APELIN RECEPTOR AGONISTS | Oct 11, 2021 | Pending |
Array
(
[id] => 17368334
[patent_doc_number] => 20220023386
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => METHOD FOR THE TREATMENT OR PREVENTION OF OSTEOARTHRITIS
[patent_app_type] => utility
[patent_app_number] => 17/498615
[patent_app_country] => US
[patent_app_date] => 2021-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7518
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 363
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498615
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/498615 | Method for the treatment or prevention of osteoarthritis | Oct 10, 2021 | Issued |
Array
(
[id] => 18806934
[patent_doc_number] => 20230381267
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => OXYTOCIN TREATMENT FOR HYPERMOBILE EHLERS-DANLOS SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/027340
[patent_app_country] => US
[patent_app_date] => 2021-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027340
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/027340 | OXYTOCIN TREATMENT FOR HYPERMOBILE EHLERS-DANLOS SYNDROME | Sep 28, 2021 | Pending |
Array
(
[id] => 18806934
[patent_doc_number] => 20230381267
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => OXYTOCIN TREATMENT FOR HYPERMOBILE EHLERS-DANLOS SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/027340
[patent_app_country] => US
[patent_app_date] => 2021-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027340
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/027340 | OXYTOCIN TREATMENT FOR HYPERMOBILE EHLERS-DANLOS SYNDROME | Sep 28, 2021 | Pending |
Array
(
[id] => 17865418
[patent_doc_number] => 20220288153
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => Methods for Treating HCV
[patent_app_type] => utility
[patent_app_number] => 17/484287
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55805
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484287
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/484287 | Methods for Treating HCV | Sep 23, 2021 | Abandoned |
Array
(
[id] => 17563093
[patent_doc_number] => 20220127242
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => N-LIPOIC-AMINO ACID OR PEPTIDE, DERIVATIVES AND THEIR USES
[patent_app_type] => utility
[patent_app_number] => 17/484929
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6431
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484929
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/484929 | N-lipoic-amino acid or peptide, derivatives and their uses | Sep 23, 2021 | Issued |
Array
(
[id] => 17314470
[patent_doc_number] => 20210403518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => BISTABLE TYPE II OPSINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/478926
[patent_app_country] => US
[patent_app_date] => 2021-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19130
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478926
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/478926 | BISTABLE TYPE II OPSINS AND USES THEREOF | Sep 18, 2021 | Pending |